Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0L3RO
|
|||
| Former ID |
DIB012699
|
|||
| Drug Name |
TAS-119
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-9: 140-199, 210-229] | Phase 1 | [1] | |
| Company |
Taiho oncology
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Aurora kinase A (AURKA) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Oocyte meiosis | |||
| Pathway Interaction Database | Aurora B signaling | |||
| Signaling by Aurora kinases | ||||
| Integrin-linked kinase signaling | ||||
| PLK1 signaling events | ||||
| Aurora A signaling | ||||
| Reactome | APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | |||
| Regulation of PLK1 Activity at G2/M Transition | ||||
| WikiPathways | EGF/EGFR Signaling Pathway | |||
| JAK/STAT | ||||
| Gastric Cancer Network 1 | ||||
| Integrated Breast Cancer Pathway | ||||
| APC/C-mediated degradation of cell cycle proteins | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800040598) | |||
| REF 2 | TAS-119, a selective Aurora A inhibitor, enhanced the antitumor efficacy of taxanes in multiple human tumor cell lines including paclitaxel-resistant cells. Molecular Cancer Therapeutics. 01/2014; 12(11_Supplement):A268-A268. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.